(Q38421169)

English

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

scientific article published on August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha (English)

1 reference

Europe PubMed Central

2 September 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Janice P Dutcher

4

object named as

Janice P Dutcher

1 reference

Europe PubMed Central

2 September 2017

author name string

Robert A Figlin

1

1 reference

Europe PubMed Central

2 September 2017

Paul de Souza

2

1 reference

Europe PubMed Central

2 September 2017

David McDermott

3

1 reference

Europe PubMed Central

2 September 2017

Anna Berkenblit

5

1 reference

Europe PubMed Central

2 September 2017

Alexandra Thiele

6

1 reference

Europe PubMed Central

2 September 2017

Mizue Krygowski

7

1 reference

Europe PubMed Central

2 September 2017

Andrew Strahs

8

1 reference

Europe PubMed Central

2 September 2017

Jay Feingold

9

1 reference

Europe PubMed Central

2 September 2017

Joseph Boni

10

1 reference

Europe PubMed Central

2 September 2017

Gary Hudes

11

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

1 August 2009

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

115

1 reference

Europe PubMed Central

2 September 2017

3651-3660

1 reference

Europe PubMed Central

2 September 2017

16

1 reference

Europe PubMed Central

2 September 2017

Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent progress in the management of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

The Heidelberg classification of renal cell tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

PI 3-kinase, mTOR, protein synthesis and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24438

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24438

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38421169&oldid=1758568060"